SCHEMBL20099873

SCHEMBL20099873

Brc1ccccc1-c1cc(-c2cccnc2)[nH]n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP1A2 P05177 1/20 0.60
HPGDS O60760 2/20 0.59
RAB9A P51151 2/20 0.49
TP53 P04637 2/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
ALK Q9UM73 1/20 0.47
POLB P06746 1/20 0.46
CYP19A1 P11511 1/20 0.46
CYP2A6 P11509 3/20 0.44
CYP2B6 P20813 3/20 0.44
CYP2E1 P05181 2/20 0.44
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
IDO1 P14902 2/20 0.43
ADORA3 P0DMS8 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28190516 0.85 RAB9A (0.65) ALDH1A1HPGDSRAB9ATP53POLB
SCHEMBL20099779 0.84 RAB9A (0.50) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL17938573 0.83 ALDH1A1 (0.60) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL27955849 0.83 ALDH1A1 (0.60) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL27730924 0.82 HPGDS (0.78) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL3078162 0.81 CYP3A4 (0.89) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL20099793 0.81 POLB (0.56) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL20099884 0.81 POLB (0.56) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
Hydrochloric Acid SCHEMBL27514609 0.80 HPGDS (0.76) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A
SCHEMBL17279983 0.79 CYP3A4 (0.77) CYP3A4ALDH1A1CYP1A2HPGDSRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3315492-B1 PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2020-09-16 EP disclosed
US-10287251-B2 Pyrazole derivative or pharmaceutically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2019-05-14 US disclosed
US-20180170879-A1 PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2018-06-21 US disclosed
US-20180170879-A1 PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2018-06-21 US disclosed
EP-3315492-A1 PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287251-B2 Pyrazole derivative or pharmaceutically acceptable salt thereof TRPM8, HCN3, HCN4 CYP3A4 854/4885ALDH1A1 2377/4885CYP1A2 2208/4885
US-20180170879-A1 PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TRPM8, HCN3, HCN4 CYP3A4 672/4885ALDH1A1 1871/4885CYP1A2 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.